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Caphosol for prevention of oral mucositis in
pediatric myeloablative haematopoietic cell
transplantation
Nathaniel Treister*,1,2, Michael Nieder3, Christina Baggott4, Ellen Olson5, Lu Chen6, Ha Dang6,7,
Mark Krailo6,7, Amanda August8 and Lillian Sung9
1

Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Oral Medicine,
Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA; 3Blood and Marrow Transplant Department, Moffitt
Cancer Center, Tampa, FL and Johns Hopkins All Children’s Hospital, St Petersburg, FL, USA; 4Pediatric Hematology-Oncology,
Stanford Medical Center, Stanford, CA, USA; 5Aflac Cancer and Blood Disorders Service, Children’s Healthcare of Atlanta, Atlanta,
GA, USA; 6Children’s Oncology Group, Monrovia, CA, USA; 7Department of Preventive Medicine, University of Southern
California, Los Angeles, CA, USA; 8Children’s Mercy Hospital, Kansas City, MO, USA and 9Division of Haematology/Oncology, The
Hospital for Sick Children, Toronto, Ontario, Canada
Background: The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at
the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and
adolescents undergoing haematopoietic cell transplantation (HCT).
Methods: This was a Children’s Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial.
Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were
randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day þ 20. Subjects were
assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0–10) and
the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO X3).
Results: The study enrolled 220 participants with a median age of 13.7 years (range 4.0–21.9); 163 (74%) received allogeneic HCT.
The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P ¼ 0.99)
recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91),
respectively (P ¼ 0.44). There were no significant differences in any of the secondary end points between the groups.
Conclusions: Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing
myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.

Oral mucositis (OM) is a painful and debilitating complication that
affects over 70% of children and adolescents undergoing
haematopoietic cell transplantation (HCT) (Scully et al, 2006;
Tomlinson et al, 2007; Vagliano et al, 2011). Clinical features of
OM include diffuse mucosal erythema and ulcerations with
accompanying mouth and throat pain, resulting in limited oral
intake and suffering that, when severe, frequently requires opioid

analgesics and total parenteral nutritional support (Sonis, 2004). In
addition, the presence of severe OM has been associated with an
increased risk of bacteraemia as well as prolonged length of
hospital stay and greater total associated hospitalisation costs
(Bochud et al, 1994; Sonis et al, 2001; Elting et al, 2003). Children
consistently report OM as the most distressing aspect of the HCT
experience (Ljungman et al, 1999; Bellm et al, 2000; Cheng, 2009).
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Although palifermin, a keratinocyte growth factor, is approved by
the US Food and Drug Administration for prevention of OM in
adults with haematologic malignancies undergoing HCT, it is
expensive, and there is limited safety and efficacy data in children
(Spielberger et al, 2004; Elting et al, 2007; Srinivasan et al, 2012;
Nooka et al, 2014; Vitale et al, 2014). Prevention and optimal
management of OM remains an important unmet need in pediatric
HCT (Sung et al, 2015).
Caphosol (EUSA Pharma, Hemel Hempstead, UK) is a
super-saturated calcium phosphate electrolyte solution that is
approved by the FDA as a device to be used as an adjunct to
standard oral care in patients with chemotherapy-associated OM
(http://www.accessdata.fda.gov/cdrh_docs/pdf3/k030802.pdf). The
mechanism of action of Caphosol remains to be elucidated, but it is
thought that the high ionic solution permeates the oral mucosa
and actives different signalling pathways, resulting in apoptosis
modulation, downregulation of mediators of pain and inflammation, and activation of wound healing and epithelial proliferation
(An et al, 1998). A single-centre phase III randomised controlled
trial that evaluated the efficacy of Caphosol in preventing OM in
adult patients undergoing HCT demonstrated statistically significant decreases in days of mucositis, pain and morphine use, as well
as total dose of morphine (Papas et al, 2003). In all clinical reports,
Caphosol has been consistently well tolerated with no reported
side effects or toxicities (Quinn, 2013). However, the efficacy of
Caphosol has not been replicated in other blinded and
randomised studies and, in particular, definitive studies in
pediatric patients have been few (Raphael et al, 2014). The
primary objective of this Children’s Oncology Group (COG)
multicentre trial was to determine whether topically administered
Caphosol, rinsed orally four times daily at the initiation of
conditioning, reduces the duration of severe OM compared with
placebo saline solution among children and adolescents undergoing myeloablative HCT.
MATERIALS AND METHODS

Study design. This was a phase III international multicentre
randomised double-blinded placebo-controlled clinical trial. This
study was registered (NCT01305200) and reporting follows the
CONSORT criteria (Rennie, 2001). The study was activated in
April 2011 and was closed to enrolment in June 2014. The study
was approved by the National Cancer Institute Central institutional
review board (IRB) and the IRB of each participating centre. All
patients and their parents or legal guardians provided written
informed consent or assent as appropriate.
Patients. Patients between the ages of 4 and 21 years who were
scheduled to undergo myeloablative autologous or allogeneic HCT
for any indication including malignant and nonmalignant conditions were eligible for study participation (Bacigalupo et al, 2009).
Permitted graft sources included bone marrow (BM), umbilical
cord blood (UCB), or cytokine-mobilised peripheral blood stem
cells (PBSCs). Eligible allogeneic donors were any human leukocyte
antigen (HLA)-matched donor or partially matched family
members (mismatched for a single HLA locus at A, B, C, or
DR), unrelated BM, PBSCs, or UCB (at least 4 of 6 loci match at A,
B, and DR). Eligible patients could not have received palifermin
within 30 days before enrolment, and could not have been
previously treated with Caphosol.
Study interventions. Caphosol was supplied as two separately
packaged aqueous solutions, a 15 ml phosphate solution (Caphosol A)
and a 15 ml calcium solution (Caphosol B), that were mixed to
form a pH neutral supersaturated solution at the time of use.
Caphosol was provided and distributed directly to the study centres
by Jazz Pharmaceuticals (Dublin, Ireland). Placebo was sterile 0.9%
22
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sodium chloride injection solution that was supplied by each site.
Saline stored in plastic bottles (e.g., single dose preservative free
0.9% sodium chloride injection used for drug reconstitution) was
used instead of saline stored in polyvinyl chloride bags as the bags
can impart an unpleasant smell and therefore could potentially
compromise blinding.
Randomisation, allocation concealment, and blinding. Patients
were randomised at enrolment to receive either Caphosol or
placebo in a 1 : 1 ratio. Randomisation was stratified by type of
graft (autologous vs allogeneic) and conditioning regimen (total
body irradiation (TBI) or melphalan, vs neither TBI nor
melphalan) and was performed in blocks of four. The allocation
sequence was computer generated by the COG statistical office and
allocation remained concealed to all health-care providers, children
and their families, and outcome assessors.
To maintain blinding of the patients, health-care providers, and
outcome assessors, the following series of procedures were
performed. Each institution had two designated unblinded site
pharmacists who were not directly involved in the care of study
patients. They were specifically instructed to not share allocation
with anyone at the site (provider or patient). For each randomised
patient, the unblinded pharmacist was responsible for dispensing
of the randomised intervention as follows. Upon enrolment of each
participant, the unblinded pharmacist contacted the COG Research
Coordinator by telephone, who verbally communicated the
treatment assignment to the pharmacist. The pharmacist was
asked to verbally repeat the treatment assignment for confirmation.
The treatment assignment was also emailed to the pharmacist. The
pharmacist then dispensed Caphosol or placebo as specified below.
Study rinse preparation and administration. Caphosol components (Caphosol A and Caphosol B, 2  15 ml) or placebo
(2  15 ml of 0.9% sodium chloride solution) were transferred by
the pharmacist into two identical oral syringes (marked ‘Syringe A’
and ‘Syringe B’) up to 4 days before use and delivered to the
patient’s ward where they were accessible by the patient’s bedside
nurse. At the time of planned administration, bedside nurses were
instructed to mix the two syringes (Syringe A and Syringe B) into a
cup and then to have the participant perform two rinses within
15 min of mixing. Nurses provided half of the mixed solution
(15 ml) for the subject to rinse their mouth thoroughly and gargle
for 1 min and spit. The same procedure was repeated with the
remaining 15 ml of solution, for a total rinse time of 2 min. For
younger children with small mouths who were unable to tolerate
the full 15 ml of mixed solution, the volume of the mixture could
be reduced to 5 to 10 ml, as tolerated. Subjects were instructed not
to swallow the solution, and to avoid eating or drinking for 15 min
after use.
Study therapy administration was initiated on the first day of
conditioning and continued daily until day þ 20 (20 days
following the date of stem cell infusion) or hospital discharge,
whichever occurred first. Subjects rinsed four times per day (two
rinses per episode) at approximately evenly spaced intervals.
Subjects who developed World Health Organisation (WHO) Grade
X3 OM were permitted to request up to two additional study
rinses per day, for a total of six rinses. In the event of a missed
dose, every effort was made to make up the missed dose before bed,
regardless of dosing interval, but individual doses could not be
combined or ‘doubled-up’.
Outcomes. The primary outcome was the WHO Oral Toxicity
grading scale (WHO, 1979). The WHO scale is the most
commonly used scale in mucositis clinical trials and it consists of
subjective, objective, and functional components, resulting in a
score that ranges from 0 to 4 (0 ¼ no mucositis; 1 ¼ oral soreness
and erythema; 2 ¼ ulcers and erythema, can swallow solid food;
3 ¼ ulcers and extensive erythema, cannot swallow solid food and
www.bjcancer.com | DOI:10.1038/bjc.2016.380
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can tolerate soft/liquid diet only; and 4 ¼ ulcers and extensive
erythema, alimentation impossible). Subjects were queried regarding their ability to eat solids, liquids only, or nothing by mouth
during the prior 24 h period. If the answer was ‘liquids’ or ‘nothing
by mouth’, it was determined whether the limitation was due to
OM-associated symptoms or due to other reasons such as nausea
or anorexia. If diet limitations were not attributed to OM, then
subjects were asked what they would otherwise be able to tolerate,
and this answer was used to generate the WHO score.
In order to apply the WHO score, the assessor had to determine
the presence or absence of erythema and ulcers. The assessor was
instructed to examine the oral cavity in a site-directed manner and
erythema or ulceration were documented for each of the following
sites: lower labial mucosa, upper labial mucosa, right buccal
mucosa, left buccal mucosa, right ventrolateral tongue, left
ventrolateral tongue, floor of mouth, and soft palate. The WHO
score was determined based on the diet answer, presence or
absence of mouth pain, and clinical exam findings.
Secondary outcomes included severity of OM according to a
Mouth Pain Categorical Rating Scale and Oral Mucositis Daily
Questionnaire (OMDQ); incidence, total dose, and duration of
opioid analgesic use (morphine equivalents); incidence and
duration of total parenteral nutrition (TPN) administration; and
the incidence of fever and neutropenia and invasive bacterial
infections. Mouth pain experienced in the last 24 h period was
rated from 0 to 10, with 0 being no pain and 10 being the worst
pain imaginable. A modified version of the Oral Mucositis Daily
Questionnaire (with diarrhoea-related questions removed), previously validated in children, was completed daily (Tomlinson
et al, 2011; Manji et al, 2012). The OMDQ consists of a 0–4 Likert
scale for each of six subscales consisting of mouth and throat pain
and impact of mouth and throat soreness on sleeping, swallowing,
drinking, eating, and talking. A summary score is not available for
the OMDQ.
The incidence and duration of TPN, fever and neutropenia,
invasive bacterial infections, and opioid analgesic drug, dose, and
duration were abstracted from patient medical records from
initiation of study rinses through day þ 20 or hospital discharge,
death, or withdrawal from study, whichever occurred first. Fever
and neutropenia was defined as a single oral temperature of
438.3 1C or a sustained temperature of X38 1C for more than 1 h
occurring during neutropenia (absolute neutrophil count o500
per ml or between 500 and 1000 per ml and falling). An invasive
bacterial infection was defined as one or more cultures positive for
a bacterial pathogen obtained from a blood culture. All opioids
were converted to morphine equivalents using commonly accepted
standards for comparisons of dose (Kamdar, 2008; Swarm et al,
2010; Chou et al, 2014; http://www.micromedexsolutions.com).
Excluded from these calculations were nonopioids reported
(n ¼ 3), when sites reported ‘dose not available/not correct’
(n ¼ 2), and missing duration (n ¼ 1).
Mucositis ascertainment. Subjects were assessed daily for OM by
trained study staff during the observation period. The trained
assessors completed the WHO scale, pain scale, and OMDQ by
direct inquiry with the participant. Assessors consisted of
physicians, nurses, and other clinical staff. Standardised OM
assessment training was conducted in person at COG meetings as
well as via live webinars. Only qualified and trained individuals
were permitted to conduct OM assessments. Daily assessments
(including weekends and holidays) were conducted starting from
day  1 of HCT and continued until: (1) refusal of further
participation for OM assessment; (2) day þ 20; or (3) discharge
home, whichever occurred first. Even if the oral rinses were not
performed, daily OM assessments were continued. In the event
that oral assessments could not be performed on a given day (e.g.,
patient intubated in intensive care), they were resumed as soon as
www.bjcancer.com | DOI:10.1038/bjc.2016.380
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possible. Consistency in the assessor for each participant was
strongly encouraged when possible.
Toxicity assessment. Subjects were assessed daily for study rinserelated toxicities using the National Cancer Institute’s Common
Terminology Criteria for Adverse Events v3.0. The following
adverse events were reported: XGrade 3 allergic reaction, XGrade
3 anaphylaxis, XGrade 3 oral pain, XGrade 2 dysgeusia, and
XGrade 3 infection with microbiologically documented positive
blood cultures.
Statistical analysis. The primary study end point was duration of
severe OM (defined as WHO score of 3 or 4) assessed daily from
day  1 through day þ 20 (22 days). Patients with less than half of
daily WHO assessments (o11 assessments) were deemed not
evaluable for OM outcomes and excluded from all OM outcome
analyses. However, all participants were included in the analyses of
non-OM secondary end points and toxicities. The planned sample
size of 200 evaluable patients (100 per arm) assumed a mean
duration of severe OM of 5 days in the placebo arm vs 3 days in the
Caphosol arm (s.d. of 5 days) and was based on a two-sample t-test
with at least 80% power at two-sided a of 0.05. Maximum study
enrolment was set at 235 patients to account for ineligible and
inevaluable enrolments.
For evaluable patients with missing daily WHO assessments,
missing daily assessments at the end of the assessment period were
imputed by the last observation carried forward; missing daily
assessments at the start of the assessment period were imputed by
the median of the observations from other patients in the same
stratum; intermittent missing daily assessments in-between two
nonmissing assessments were imputed by linear interpolation. As
the WHO score imputed by linear interpolation may not take
integer values 1 to 4, an imputed WHO score of X2.5 was
considered severe OM.
Area under the curve (AUC) of the OMDQ subscales and
Pain Categorical Rating Scale from day  1 to day þ 20 was
calculated for patients evaluable for OM outcomes. In AUC
calculation, missing daily assessments were imputed the same
way as missing WHO score imputation described above. The
missing data imputation approach for AUC only affected the
AUC value if there were missing data at the start or the end of
the assessment period, as AUC in-between two nonmissing
assessments was identical to the missing data imputation by
linear interpolation.
Approach was intention to treat and all participants were
analysed in the arm to which they were randomised. Randomised
patients not evaluable for OM outcomes (as described above) or
randomised patients without data for secondary end points were
excluded in the respective analyses. Continuous measures were
compared between the two arms by two-sample t-tests. Categorical
measures were compared between the two arms by w2 test. All tests
were two sided with P-values of o0.05 considered statistically
significant.
RESULTS

Patient characteristics. A total of 226 participants were identified;
4 were not eligible (mismatched donor, n ¼ 1; nonmyeloablative
conditioning, n ¼ 2; incorrect short-form consent signed, n ¼ 1)
and 2 were not randomised (sites were unable to reach the
coordinating office because of time change difference or holidays).
Thus, 220 eligible children and adolescents were randomised with a
median age of 13.7 years (range 4–21.9 years; Table 1). Among the
220 randomised participants, 10 did not receive any protocol
treatment (6 in Caphosol arm and 4 in placebo arm; Figure 1)
because of subject refusal (n ¼ 5), consent withdrawal (n ¼ 3), or
physician choice (n ¼ 2). The majority were being treated for
23
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Table 1. Baseline characteristics of the study cohort by
allocation

Median age in years (range)

Placebo,
N ¼ 110 (%)

Caphosol,
N ¼ 110 (%)

13.7 (4.1–21.9)

13.7 (4.0–20.9)

Sex
Male
Female

56 (50.9)
54 (49.1)

62 (56.4)
48 (43.6)

Diagnosis
Malignant conditions
Nonmalignant conditions

99 (90.0)
11 (10.0)

99 (90.0)
11 (10.0)

Transplant type
Autologous
Allogeneic

28 (25.5)
82 (74.5%)

29 (26.4)
81 (73.6)

Graft source
Bone marrow
Peripheral blood stem cells
Umbilical cord blood

49 (44.6)
47 (42.7)
14 (12.7)

57 (51.8)
44 (40.0)
9 (8.2)

Conditioning with TBI or melphalan

70 (63.6)

71 (64.5)

Characteristics in allogeneic group
Matched related donor
Mismatched related donor
Matched unrelated donor
Mismatched unrelated donor
Matched or partially mismatched
cord blood

n ¼ 82
26 (31.7)
0 (0)
33 (40.2)
9 (11)
14 (17.1)

n ¼ 81
31 (38.3)
1 (1.2)
28 (34.6%)
12 (14.8)
9 (11.1)

GVHD prophylaxis with methotrexate
Mean day of engraftment (range)

46/72a (63.9)
14.3 (9–34)

50/72a (69.4)
14.3 (8–24)

Abbreviations: GVHD ¼ graft vs host disease; TBI ¼ total body irradiation.
a
Patients without data on GVHD prophylaxis data were excluded.

malignant conditions and received primarily bone marrow or
PBSCs grafts. Most participants underwent allogeneic HCT, with
the majority receiving conditioning regimens that included TBI or
melphalan.
Study rinse and OM assessment compliance. Of the 220 (110 per
arm) randomised subjects, 158 (72%, 79 per arm) received X2
rinses per day on average (mean rinses per day ¼ 3.6; mean total
rinses ¼ 95.5), and 62 (28%, 31 per arm) received o2 rinses per
day on average (mean rinses per day ¼ 0.72; mean total
rinses ¼ 20.2). With respect to age, subjects 4–12 years old
completed a mean±s.d. of 2.5±1.5 rinses per day and subjects
412–21 years old completed a mean of 3.0±1.3 rinses per day.
There was no difference in mean rises per day (placebo ¼ 3.6
(s.e. ¼ 0.05) vs treatment ¼ 3.6 (s.e. ¼ 0.05), P ¼ 0.70) or mean total
rinses (placebo ¼ 96.0 (s.e. ¼ 2.0) vs treatment ¼ 95.0 (s.e. ¼ 2.0),
P ¼ 0.72) between treatment arms.
There were 38 subjects (19 in each arm) who were inevaluable
for the primary end point because of an insufficient number of
completed WHO assessments (o11 days). All of the participants
who were enrolled but did not receive any protocol treatment
(n ¼ 10) were inevaluable because of the absence of any mucositis
assessments. Of the 38 inevaluable subjects, 24 had no OM
assessments. The 182 patients (182 out of 220, 83%) with X11
daily WHO scores (mean ¼ 19.7, range 11–22) were therefore
evaluable for primary and secondary end point analyses. Evaluable
participants, when compared with nonevaluable participants, were
not significantly different with respect to the patient characteristics
variables reported in Table 1 (data not shown).
WHO Oral Toxicity Score end points. Table 2 and Figure 2
illustrate that with respect to the primary study end point, the
mean±s.d. days of severe OM was not reduced among Caphosol
(4.5±5.0 days) vs placebo (4.5±4.8 days; P ¼ 0.99) recipients. The
mean treatment difference between study arms was 0 (95%
24

confidence interval  1.4 to 1.4). When limiting the primary
analysis to subjects with an average of X2 daily rinses, there was
no difference in mean±s.d. days of severe mucositis between the
Caphosol (4.3±5.0 days) and placebo (4.2±4.7 days; P ¼ 0.88)
arms. The incidence of severe OM (WHO X3) in the Caphosol
and placebo arms was 63% (57 out of 91) and 68% (62 out of 91),
respectively (P ¼ 0.44).
Secondary end points. There were no statistically significant
differences in the Mouth Pain Categorical Rating Scale,
OMDQ subscales, incidence, duration or total dose of opioids,
incidence and duration of TPN, incidence of fever and
neutropenia, or incidence of invasive bacterial infection between
the Caphosol and placebo arms (Tables 2 and 3 and Supplementary
Table 1).
Adverse events. There were no toxicities that were attributed to
study rinses. There were three deaths reported on treatment or
within 1 month of the end of treatment, none of which were
attributed to study rinses.
DISCUSSION

In this international, multicentre randomised double-blinded trial,
Caphosol did not reduce the duration of severe OM (WHO score
X3) compared with placebo in pediatric and adolescent patients
undergoing myeloablative HCT. There were also no differences
between the two arms in any of the study’s secondary end points.
Consequently, this study does not support the routine use of
Caphosol for prevention of OM in children and adolescents
undergoing myeloablative HCT.
Our results are concordant with other recently reported
prospective, randomised, placebo-controlled studies evaluating
Caphosol for prevention of OM in HCT. Raphael et al (2014)
reported a prospective multicentre double-blind randomised
controlled trial evaluating interventional (rather than preventive)
Caphosol vs 0.9% saline placebo in children (4–18 years old)
undergoing chemotherapy alone or HCT. Study rinses were
initiated following onset of OM, and all end points between the
two groups were similar. Svanberg et al (2015) reported a
randomised controlled open-abel trial of cryotherapy with or
without Caphosol for prevention of OM in patients undergoing
allogeneic HCT, with no differences in OM between the two
groups.
As a topically applied agent, compliance with daily Caphosol
rinses would be expected to be an important factor affecting
treatment efficacy and effectiveness. Compliance with the prescribed study rinses was not described in any of the prior reports of
Caphosol for OM prevention, and this is an important limitation of
those publications. In our study, of the 220 randomised patients,
72% received X2 rinses per day on average with no difference
between the two study arms. This finding suggests that oral rinses
that require multiple daily administrations may not be feasible in
children and adolescents undergoing HCT as 28% were not able to
maintain this intensity of oral rinses. Although this observation
provides important insight into regimens likely to be successful in
future studies, the sensitivity analysis among patients receiving on
average two rinses per day also failed to show a benefit of
Caphosol, further strengthening our conclusion of its lack of
efficacy.
In the current study, rinses were generally well tolerated,
although there were some anecdotal reports describing an
unpleasant ‘salty’ taste. The study by Wasko-Grabowska et al
(2011) described one subject (1 out of 32, 3.1%) who had ‘problems
with the taste’ of Caphosol, but any potential impact on regimen
compliance was not reported. The study by Svanberg et al (2015)
reported one subject who stopped Caphosol rinses because of
www.bjcancer.com | DOI:10.1038/bjc.2016.380

Caphosol for mucositis prevention in children

BRITISH JOURNAL OF CANCER

Enrolment
Enrolled (n = 226)

Excluded (n = 6)
♦ Ineligible (n = 4)
♦ Not randomised* (n = 2)
Eligible and randomised (n = 220)

Allocation
Allocated to Caphosol (n =110)
♦ Received some allocated intervention (n =104)
♦ Did not receive allocated intervention (n = 6, 4
refusal, 2 physician’s choice)

Allocated to saline placebo (n =110)
♦ Received some allocated intervention (n =106)
♦ Did not receive allocated intervention (n = 4, 3
consent withdrawal, 1 refusal)

Primary Analysis
♦ Excluded from analysis (<11 daily WHO)
(n =19)

♦ Excluded from analysis (<11 daily WHO)
(n =19)

Analysed (n = 91)

Analysed (n = 91)

Figure 1. Flow diagram of patient enrolment, allocation, and analysis. *Site unable to contact randomisation centre and subjects therefore never
randomised before starting conditioning.

Table 2. Primary and secondary mucositis end points in evaluable patients by allocationa
Placebo, N ¼ 91

Caphosol, N ¼ 91

P-valueb

WHO mucositis scale (primary end point)
Mean days of severe (WHO Grade 3 or 4) mucositis (s.d.)

4.5 (4.8)

4.5 (5.0)

Incidence of severe oral mucositis

62 (68%)

57 (63%)

Maximum WHO Grade
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4

0.44
0.46

2
8
19
42
20

(2.2%)
(8.8%)
(20.9%)
(46.2%)
(22.0%)

7
7
20
35
22

(7.7%)
(7.7%)
(22.0%)
(38.5%)
(24.2%)

Evaluable patients with average of X2 daily doses

76 (83.5%)

77 (84.6%)

Mean days of severe mucositis (s.d.)

4.2 (4.7)

4.3 (5.0)

Pain Categorical Rating Scale (range 0–10)c
Mean AUC (s.d.)

0.99

0.88

0.78
45.5 (36.0)

44.0 (35.6)

22.3
9.3
21.4
21.7
27.9
12.2

21.4
7.3
19.9
20.6
26.6
12.0

Oral Mucositis Daily Questionnairec
Mouth and throat pain: mean AUC (s.d.)
Sleeping: mean AUC (s.d.)
Swallowing: mean AUC (s.d.)
Drinking: mean AUC (s.d.)
Eating: mean AUC (s.d.)
Talking: mean AUC (s.d.)

(14.8)
(10.9)
(15.7)
(16.3)
(19.4)
(11.5)

(15.7)
(9.0)
(15.9)
(17.3)
(20.7)
(13.2)

0.70
0.17
0.53
0.66
0.65
0.94

Abbreviations: AUC ¼ area under the curve; WHO ¼ World Health Organisation.
a
Evaluable patients defined as patients with X11 daily WHO assessments.
b
Categorical variables compared using w2 test and continuous variables compared using a two-sampled t-test.
c
Missing daily scores at the end of study period were imputed by last value carried forward before calculating AUC.

disagreeable taste. Of note, the study by Raphael et al (2014) was
conducted in children aged 4 to 18 years randomised to NaCl 0.9%
or Caphosol and reported that no patients dropped out because of
intolerance/bad taste, although compliance was not described. In
the current study, the reason for missed rinses was only collected
when no daily rinses were completed, but not when less than four
were completed; therefore, the true extent to which taste/
www.bjcancer.com | DOI:10.1038/bjc.2016.380

tolerability (or other factors) affected compliance (in either study
arm) is unknown.
This study had a number of strengths and potential advantages
over prior Caphosol studies. This was a well-designed centrally
administrated prospective international multicentre randomised
placebo-controlled clinical trial with objectively measured end
points. All participating study staff members were trained either in
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Figure 2. Average daily mucoistis scores among those randomised to
caphosol vs placebo. Average daily mucositis scores include
nonimputed data.

Table 3. Secondary end points by allocation
Placebo,
(N ¼ 106a)
Opioid administration
Yes
No
Morphine equivalent dose in
mg kg  1 per day
Median (range)
Mean opioid duration in days (s.d.)
Total parenteral nutrition
Yes
No
Mean TPN duration in days (s.d.)
Fever and neutropenia
Yes
No
Invasive bacterial infection
Yes
No

Caphosol,
(N ¼ 104a) P-valueb
0.52

94 (88.7%)
12 (11.3%)

95 (91.3%)
9 (8.7%)

N ¼ 90

N ¼ 86

0.4 (0–33.2)

0.3 (0–13.4)

14.2 (9.5)

12.5 (8.7)

We thank the patients, families, and study staffs from all of the
participating study sites in the United States, Canada, and
Australia/New Zealand. We thank the Children’s Oncology Group
Operations Center for coordinating the randomisation process.
We thank Jazz Pharmaceuticals for supplying and shipping
Caphosol to the study sites. This research was supported by the
following grants from the National Cancer Institute, National
Institutes of Health: The Children’s Oncology Group Chair’s Grant
U10CA98543–08, NCTN Operations Center Grant U10CA180886,
NCTN Statistics & Data Center U10CA180899, and Statistics &
Data Center Grant U10CA098413.

0.43c
0.18

CONFLICT OF INTEREST

0.30
83 (78.3%)
23 (21.7%)
13.6 (9.9)

75 (72.1%)
29 (27.9%)
11.4 (8.9)

The authors declare no conflict of interest.
0.08
0.73

69 (65.1%)
37 (34.9%)

70 (67.3%)
34 (32.7%)
0.76

7 (6.6%)
99 (93.4%)

8 (7.7%)
96 (92.3%)

Abbreviation: TPN ¼ total parenteral nutrition.
a
Ten randomised patients did not receive any treatment and did not submit reporting
period data.
b
Categorical variables compared using w2 test and continuous variables compared using a
two-sampled t-test.
c
Wilcoxon rank sums test.

person or by webinar to ensure consistent study rinse administration, OM evaluation, data collection, and submission across sites
and investigators. Furthermore, pediatric-specific considerations in
how to administer the WHO Toxicity Scale are rarely considered
but important as children undergoing cancer therapy do not eat or
drink for many reasons other than mouth pain (Tomlinson et al,
2008). The study accrued more quickly than anticipated, highlighting the enthusiasm among investigators in finding a safe and
effective intervention to limit the morbidity associated with OM.
However, our study should be interpreted in light of its
weaknesses. Our study, likely many mucositis trials, was limited by
missing data and nonevaluable subjects. In addition, the patient
population was heterogeneous and supportive care was not
standardised. However, these aspects should not have greatly
affected our trial results as all HCT regimens were considered
myeloablative and there are a paucity of approaches known to
reduce OM in this patient population. Furthermore, although all
patients underwent dental clearance per institutional guidelines
before the start of the transplant conditioning regimen, we did not
collect pretransplant dental evaluation or ongoing oral care,
26

although we have no reason to believe oral health status or care
would have differed between randomised groups. Finally, the
number of final evaluable subjects was lower than the originally
planned sample size, and thus our study was underpowered to
statistically demonstrate the specified effect size. However,
description of the difference and 95% CI around the primary
end point illustrates a lack of difference between randomised
groups.
In conclusion, Caphosol did not reduce severe OM when
compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.
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